Search

everythinglearnresearchcommunity

for

Search:↓

SHBG may be a useful early indicator and treatment target for PCOS.

The conclusion suggests that prostate cancer should be classified by castration status and that new therapies targeting androgen receptor signaling show promise.

MENT could be a better option than testosterone for male hormone therapy and birth control because it works well at lower doses and has fewer side effects on the prostate.

The guideline recommends mental health involvement in diagnosing gender identity disorder and outlines hormone and surgical treatment protocols, emphasizing safety, informed consent, and long-term monitoring.

Menopause and aging can affect women's quality of life and sexuality, but hormone therapies may help alleviate these issues.

Hormone therapy affects hair growth in transgender individuals, with testosterone potentially causing hair loss in trans men and estrogen reducing facial/body hair in trans women; treatment options vary.

The conclusion is that lifestyle changes and weight loss are first-line treatments for infertility due to anovulation, with various medications and assisted reproductive technologies as additional options.

COVID-19 and hypopituitarism (reduced pituitary gland function) are linked, with the latter's related health issues potentially worsening COVID-19 outcomes, and COVID-19 possibly increasing risk for pituitary complications.

A 7-year-old boy with a brain tumor developed early puberty, which was successfully treated with medication.

Polycystic Ovary Syndrome (PCOS) is a common condition in women that can cause metabolic, reproductive, and psychological issues, and requires lifestyle changes and medication for management.

The European Society of Endocrinology advises individualized long-term management for PCOS, focusing on lifestyle changes, accurate diagnosis, and treatments for associated health risks and symptoms.

PCOS starts in adolescence with hormonal issues, leading to adult health problems, and early treatment is crucial.

The research found how GPCR Class A Rhodopsin receptors are related and suggested possible substances they interact with.

Amenorrhea, or the absence of periods, should be evaluated by age 15 or within five years of early breast development, and is most commonly caused by conditions like polycystic ovary syndrome and hypothalamic amenorrhea.

Finasteride helps induce ovulation in nonresponder PCOS women.

Sex hormones affect reproduction, sexual development, and oral health, and it's important for dental practitioners to understand their effects and interactions.

The document concludes that insulin resistance is key in PCOS development and early treatment is crucial to prevent complications.

AMH helps estimate ovarian reserve but doesn't predict pregnancy chances; age is more important.

The document concludes that correct diagnosis and management of PCOS are important, and more research is needed on its risks and treatments.

Parathyroid hormones are important for hair growth, but their use in treating hair loss from chemotherapy is still uncertain.

ERβ has potential in treating prostate cancer and neurodegenerative diseases, but human studies are needed before clinical use.

Testosterone is crucial for development, growth, and various body functions in mammals.

The document concludes that individualized treatment and lifestyle changes are important for managing menopause symptoms and health risks.

Androgens and SARMs play a role in body mass, frailty, skin health, and hair growth, and are used in treating prostate cancer, acne, and hair loss, with potential for new uses and improved versions in the future.

Eating high-glycemic and dairy foods can increase hormones that may cause acne and other health issues.

Skin changes can help diagnose and manage endocrine disorders like thyroid problems, diabetes, and adrenal gland conditions.

Amenorrhea is relatively rare and initial testing should check FSH, TSH, and prolactin levels.

Hormones are crucial for regulating body functions and imbalances can lead to health issues.

The document concludes that identifying the cause of amenorrhea is crucial for proper treatment.

Amenorrhea is when a woman doesn't have periods, with primary amenorrhea starting by age 15 or within five years of breast development, and secondary amenorrhea when periods stop for three months. It affects 3-4% of women not pregnant, breastfeeding, or in menopause, mainly due to polycystic ovary syndrome, hypothalamic amenorrhea, hyperprolactinemia, and ovarian failure.